Longboard Pharmaceuticals is developing therapies for patients with neurological and rare diseases. Many important categories of drugs target G protein-coupled receptors (GPCRs) that regulate various biological processes within cells. Longboard was conceived to advance a portfolio of drugs that are highly selective for GPCs using their expertise in drug development and optimization. Their lead program, LP352, is an oral small molecule that binds the GPCR 5-HT2C, which Longboard is testing as a treatment of seizures associated with patients with Developmental and Epileptic Encephalopathy syndromes.

Longboard Pharmaceuticals


              Lundbeck | LinkedIn
            

LBPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Longboard Pharmaceuticals, Inc. Is Fair to Shareholders - Business Wire

 Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline 

Lundbeck signs $2.5B check for Longboard, seeing blockbuster potential in epilepsy med - Fierce Biotech

Longboard reports interim data from Phase II extension trial of DEEs treatment - Clinical Trials Arena

Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire

Longboard Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates - Business Wire

Andreas Halvorsen's Strategic Acquisition in Longboard Pharmaceuticals - Yahoo Finance

Lundbeck to Buy Longboard Pharma in $2.6 Billion Deal - Bloomberg

Lundbeck Deepens Neuro, Rare Disease Portfolio With $2.6B Longboard Buy - BioSpace

Firm Advises Evercore on Longboard Pharmaceuticals’ $2.6 Billion Acquisition by Lundbeck - Wilson Sonsini

We are pleased to be chosen as one of the Best Places to Work in San Diego - Thank you to the San Diego Business Journal for this honor! At Longboard, we foster a company culture that is both collaborative and inclusive, and we believe that is essential for innovation and success. We are driven by our common mission to develop novel, transformative medicines for people living with devastating neurological conditions.  

Longboard Pharmaceuticals' SWOT analysis: bexicaserin stock poised for growth - Investing.com

 Recap: Longboard Pharmaceuticals Q4 Earnings 

 Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs) 

 Longboard Pharmaceuticals raises ~$241.5M through public offering of shares (NASDAQ:LBPH) 

 Longboard Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters ... 

 Longboard Pharmaceuticals announces topline data from bexicaserin study 

Lundbeck picks up Longboard Pharmaceuticals for $2.6B - MM+M Online

Longboard Pharmaceuticals Announces Positive Interim Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs) - Business Wire

 Longboard Stock Skyrockets on Positive Epilepsy Data, Plans $150M Public Offering 

LBPH Stock Soars 51% as Lundbeck Acquires Longboard Pharmaceuticals for $2.6 Billion - MoneyCheck

Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - StockTitan

 Longboard Pharmaceuticals HSR waiting period expires for Lundbeck deal 

 Roberts Leads Longboard Through Clinical-Stage Growth 

Longboard Pharmaceuticals Receives Rare Pediatric Disease Designation and Orphan Drug Designation for Bexicaserin (LP352) in Dravet Syndrome - Business Wire

Longboard Pharmaceuticals Receives Breakthrough Therapy Designation for Bexicaserin (LP352) - Business Wire

We are thrilled to be the first partner in the Allies in Research Program with the Pediatric Epilepsy Research Consortium! We look forward to collaborating with this amazing network to support the pediatric epilepsy community.   

Lundbeck highlights commitment to the rare epilepsy community at American Epilepsy Society (AES) Annual Meeting with data presentations

Lundbeck completes acquisition of Longboard

Today, we announced positive interim results from our ongoing open-label extension (OLE) of the PACIFIC Study evaluating bexicaserin in participants with DEEs. Our CMO, Randall Kaye, presented these data at the International League Against Epilepsy 15th European Epilepsy Congress. For more detail on the OLE results visit the following link https://bit.ly/4ed1KPP #EEC2024 #EEC

 Longboard Pharmaceuticals EPS of -$0.42 beats by $0.07 

Longboard Pharmaceuticals Initiates Phase 3 DEEp SEA Study Evaluating Bexicaserin in Dravet Syndrome - Business Wire

 Behind The Huge Rally In Longboard Pharmaceuticals (NASDAQ:LBPH) 

 Longboard Pharmaceuticals prices 10M share secondary at $21, Bloomberg says 

STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Longboard Pharmaceuticals, Inc. - LBPH - PR Newswire

Lundbeck doubled its offer for Longboard over six months, new filing shows - Endpoints News

 Longboard Pharmaceuticals granted Orphan Drug Designation for bexicaserin 

 Lundbeck to acquire Longboard Pharmaceuticals for $60.00 per share, or $2.6B 

 Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) 

 Longboard Pharmaceuticals initiates DEEp SEA Study 

 Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Good Position To Deliver On Growth Plans 

 Longboard Pharmaceuticals 10M share Secondary priced at $21.00 

Shareholder Alert: Ademi LLP Investigates Whether Longboard Pharmaceuticals, Inc. Is Obtaining a Fair Price for Its Public Shareholders - Business Wire

Longboard Pharmaceuticals to Participate in Four Upcoming Investor Conferences in September - Business Wire

Longboard Pharmaceuticals Provides Corporate Update and Reports Full Year 2021 Financial Results

 Longboard Pharmaceuticals Receives Breakthrough Therapy Designation for Bexicaserin (LP352) 

Why Is Epilepsy Focused Longboard Pharmaceuticals Stock Trading Higher On Monday? - Yahoo Finance

Longboard Pharmaceuticals stock soars to all-time high of $59.48 - Investing.com

Lundbeck Agrees to Acquire Longboard Pharmaceuticals - Contract Pharma

Denmark: Lundbeck to acquire Longboard Pharmaceuticals - Investors in Healthcare

Sr. Manager, Medical Information – Longboard Pharmaceuticals, Inc. – Career Page (applytojob.com)

Lundbeck’s Neuro-Rare Pipeline Lands Cornerstone Drug via $2.6B Longboard Pharma Acquisition - MedCity News

Lundbeck Acquires Longboard Pharmaceuticals for $2.6 Billion - TipRanks

 Longboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of ... 

Lundbeck to acquire Longboard Pharmaceuticals in strategic deal - PharmaTimes

 Why Longboard Pharmaceuticals Stock Is Falling 

 Longboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates 

Lundbeck announces expiration of Longboard tender offer and that all tender offer conditions are fulfilled

 Biotech Stock Longboard Catapults 316%, Leading A Biotech Rally — Here's Why 

Lundbeck to take over Longboard Pharma in US$2.6bn transaction - European Biotechnology News

Thank you to everyone who attended our R&D Day in NYC yesterday! The replay is available here. https://bit.ly/3OEgIEd

Longboard Pharmaceuticals shares soar on $2.6 billion Lundbeck acquisition deal - Investing.com

 Longboard Pharmaceuticals files for mixed shelf offering 

Lundbeck acquires Longboard Pharmaceuticals in $2.6 billion deal - OutSourcing-Pharma.com

Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates - Business Wire

Longboard Pharmaceuticals to Host Investor & Analyst Event in New York on September 16, 2024 - Business Wire

Longboard Pharmaceuticals Announces Positive Interim Analysis Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs) - Business Wire


              Longboard Life - Longboard Pharmaceuticals
            

 Longboard Pharmaceuticals to Participate in Four Upcoming Investor Conferences in September 

 Longboard Pharmaceuticals Announces Positive Interim Results from the Open-Label Extension (OLE) of the Phase 1b ... 

 Longboard Pharmaceuticals Reports Full Year 2023 Financial Results and Provides Corporate Updates 

Updated: Lundbeck makes $2.6B cash move for Longboard a month after starting Phase 3 in Dravet syndrome - Endpoints News

 Longboard Pharmaceuticals GAAP EPS of -$2.39 beats by $0.02 

Longboard Pharmaceuticals to Report Second Quarter 2024 Financial Results and Host Corporate Update Call on August 1 - Business Wire

We Think Longboard Pharmaceuticals (NASDAQ:LBPH) Can Afford To Drive Business Growth - Simply Wall St

Longboard Pharmaceuticals stock soars amid Lundbeck deal to acquire the company - MarketWatch

Denmark's Lundbeck bets on epilepsy drug with $2.6 bln Longboard deal - Reuters

Longboard Pharmaceuticals Shares Hit All-Time High on Takeover by Lundbeck - MarketWatch

 Longboard Pharmaceuticals stock gains amid takeover speculation 

Lundbeck to buy brain drug developer Longboard for $2.6B - BioPharma Dive

Longboard Pharmaceuticals' SWOT analysis: bexicaserin potential drives stock outlook - Investing.com

Lundbeck to acquire Longboard Pharmaceuticals for $60.00 per share, or $2.6B - TipRanks

 Longboard Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates 

Lundbeck signs $2.5B check for Longboard and ...

Today, we announced Rare Pediatric Disease and Orphan Drug designations for bexicaserin in Dravet syndrome - another terrific regulatory milestone! Additional details available here https://bit.ly/3XzAKna

Lundbeck to acquire Longboard Pharmaceuticals for $2.6bn - Pharmaceutical Technology

Lundbeck to buy neurology-focused Longboard Pharmaceuticals in $2.6 billion deal - STAT

 SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates B, LBPH, ZUO on Behalf of Shareholders 

Longboard Pharmaceuticals Appoints Life Sciences Executive Dr. Jane Tiller to Board of Directors

Another great accomplishment for our team! We are so pleased to announce that we initiated our Phase 3 DEEp Program - starting with DEEp SEA in #DravetSyndrome. Please click here for additional detail. https://bit.ly/4eDV4uj

We are pleased to announce the initiation of our Ph 3 DEEp OCEAN Study for individuals living with Developmental and Epileptic Encephalopathies (DEEs). We are very proud of the team for their hard work and dedication to the DEEp Program!  https://bit.ly/3YKaNSk


LONGBOARD PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Longboard Pharmaceuticals, Inc. - LBPH - Business Wire

Thank you to Patrick R. Trucchio & H.C. Wainwright & Co., LLC for hosting us at the 26th Annual Global Investor Conference. A webcast of our fireside chat with our CFO, Brandi Roberts is available here. https://bit.ly/4dUchzZ #HCWainwrightGlobal

Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs) - Business Wire

Lundbeck to acquire Longboard Pharmaceuticals in $2.6B deal - Yahoo Finance

Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline - Business Wire

H. Lundbeck to Buy Longboard Pharmaceuticals for $2.6 Billion -- Update - MarketWatch

Longboard Pharmaceuticals

Business:

Drug notes:

About: